Novo-Nordisk A/S NVO

Mr Knudsen joined Novo Nordisk in 1999 as a business analyst in NNIT A/S, previously a subsidiary of Novo Nordisk, and has since held finance positions of growing size and complexity throughout the Novo Nordisk value chain. From 2010 to 2014 Mr Knudsen was corporate vice president for Finance & IT at Novo Nordisk Inc. in the US and in 2014 he was appointed senior vice president of Corporate Finance in Novo Nordisk. In February 2018 Mr Knudsen was promoted to executive vice president and chief financial officer. In 2019 Mr Knudsen assumed further responsibilities as his area was expanded to cover Finance, Legal & Procurement, followed by a further expansion in 2022 where he assumed responsibility for Global Solutions.

Kasim Kutay, British. Chief executive officer of Novo Holdings A/S. Member of the board of directors of Novonesis A/S. Former positions- Managing director, co-head of Europe and member of the global management committee of Moelis & Co., 2009-2016. Managing director and head of Financial Solutions Group of SUN Group, 2007-2009. Positions at Morgan Stanley, including chair of the European Healthcare Group, 1989-2007. Member of the board of trustees of Northwick Park Institute for Medical Research, 2005-2016. Member of the board of governors (2006-2011) and the investment committee (2011-2016) of the School of Oriental and African Studies (SOAS). Education- 1987: MSc in Economics, the London School of Economics, UK. 1986: BSc in Economics, the London School of Economics, UK.

Ms. Liselotte Hyveled, Chief Patient Officer and Principal Vice President of Patient Voice Strategy & Alliances, Novo Nordisk A/S. Member of the board of directors of TriSalus Life Sciences. Employee-elected member of the Board of Directors since March 2022 for a term of four years (term expires in March 2026). Previously employee-elected member of the Board of Directors from 2014-2018. Education- 2018: Board Leadership Programme, Copenhagen Business School, Denmark. 2014: Board Leadership Masterclass, Copenhagen Business School, Denmark. 2011: Master of Medical Business Strategy, Copenhagen Business School, Denmark. 1992: MSc, Pharmacy, University of Copenhagen, Denmark.

Ms. Elisabeth Dahl Christensen, Full-time union representative in Novo Nordisk A/S. Education- 1989: Laboratory technician from Slagteriskolen in Roskilde, Denmark.

Ms Chow joins Novo Nordisk in February 2026 as executive vice president of Product & Portfolio Strategy. Ms Chow joins Novo Nordisk from Merck KGaA in Germany. As member of the Merck Healthcare Executive Committee. Ms Chow held the role of executive vice president and head of China and International, overseeing the healthcare business outside of North America. She also served as global head of the Cardiovascular, Metabolism, and Endocrinology portfolio, which included therapies for diabetes, cardiovascular, thyroid, and growth disorders. In addition, Ms Chow was responsible for Global Health and Health Equity. Previously, Ms Chow has held leadership roles of increasing global, regional and country responsibility in the pharmaceutical industry, including leadership position at Roche, where she led the pharmaceutical business in China, and at Bayer Healthcare in versatile roles. Before joining the pharmaceutical industry in 1997 Ms Chow started her career as a business analyst for Deloitte Consulting in London. Ms Chow is a non-executive director of the Supervisory Board of Beiersdorf AG, Germany.

Ms. Elin Jager, Senior vice president, chief of staff to CEO; Corporate Strategy & Sustainability. Ms Jager has been with Novo Nordisk since 2012, starting as a Business Process Graduate and advancing through various marketing and strategic roles across Novo Nordisk both in HQ and affiliates. For the past eight years, she has served as the executive assistant and most recently corporate vice president for Corporate Affairs to the executive vice president of International Operations. As of 1 September 2025, Ms Jager was promoted to senior vice president and chief of staff to the CEO of Novo Nordisk. As part of her role, she also heads up the corporate strategy responsibility in addition to her global sustainability efforts.

Mr Millar joins Novo Nordisk in February 2026 as executive vice president of US Operations and president of Novo Nordisk Inc. Mr Millar brings over 30 years of leadership and industry experience, including leading several launches in large chronic diseases, such as asthma, COPD, and Major Depressive Disorder, as well as targeted therapies in oncology, blood disorders, and speciality therapeutics, and integrating Direct-to-Consumer (DTC) strategies. Mr Millar is a recognised expert in US commercial launches, Gross-to-Net/Payer strategies, R&D and Commercial planning, and product life-cycle management. Before joining Novo Nordisk, Mr Millar worked for UnitedHealth Group as CEO of Optum Speciality Holdings. During his tenure with UnitedHealth, he also led Industry Relations, with responsibility for formulary management, manufacturer contracts, wholesaler agreements, network pharmacy agreements, and Optum Life Sciences. Mr Millar had a distinguished 20-year career at GlaxoSmithKline PLC, including roles as Senior Vice President of Managed Markets and Government Affairs, and Vice President/General Manager of the US Oncology Business Unit. Mr Millar began his career with Procter & Gamble Pharmaceuticals, working in the US and the UK. Mr Millar holds no other management positions.

Mr. Stephan Engels was elected to the board at the Extraordinary General Meeting, effective 14 November 2025. Member of the Board of SimCorp A/S. Former positions- CFO of Danske Bank, 2020-2025. CFO at Commerzbank AG, 2012-2020. Member of the Executive Committee of the Mercedes-Benz Car Group for Finance & Controlling and Head of Management Group Controlling at Daimler AG, 2007-2012. Member of the Board for Credit then CFO and IT at DaimlerChrysler Bank AG, 2004-2007. Education- 1999: Executive Education - Managing Global Opportunities, Harvard University, USA. 1987: MA Business Administration at University of St. Gallen, Switzerland.

Mr Helfgott joined Novo Nordisk in April 2019 as executive vice president for Rare disease. In 2025, Mr Helfgott assumed further responsibilities as his area was expanded to cover Product & Portfolio Strategy, which incorporates Global Medical Affairs and Business Development as well as the commercial teams across all therapy areas. Effective 3 April 2025, Mr Helfgott assumed the responsibility for Product & Portfolio Strategy, including commercial strategy, medical affairs and business development across all therapy areas. Mr Helfgott joined Novo Nordisk from AstraZeneca, UK, where he was global vice president in charge of the company's cardiovascular, metabolism and renal global franchise. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. Prior to this, Mr Helfgott was with McKinsey & Company in Paris, Moscow and Brussels from 1998 to 2005. Mr. Ludovic Helfgott resigned on 15 February 2026. .

Dr Lange joined Novo Nordisk in 2002, as first operationally and subsequently medically responsible for several projects within Global Development. From 2006 to 2008 Dr Lange worked in Novo Nordisk Inc., US, in the Medical Department as senior medical director. In 2008, he moved back to Denmark and became vice president, Medical & Science liraglutide, transferring in 2010 to insulin degludec in a similar position. From 2013 to 2017, he served as corporate project vice president for Insulin & Diabetes Outcomes and subsequently Insulin & Devices. In January 2018, he was appointed senior vice president for Global Development. In March 2021, Dr Lange was appointed executive vice president for Development, and in August 2025 Dr Lange took over responsibility of the newly consolidated R&D EVP area, when the two EVP areas Research & Early Development and Development were merged and also appointed chief scientific officer (CSO). From 1997 to 2002, Dr Lange did clinical work as well as clinical research of which the latter, three years at the Department of Endocrinology, National University Hospital, Denmark. Dr Lange has served on the board of directors of Beta Bionics Inc., US.

Ms. Britt Meelby Jensen was elected to the board at the Extraordinary General Meeting, effective 14 November 2025. CEO of Ambu A/S. Member of the Board of Novo Holdings A/S. Member of the Board of Hempel A/S. Former positions- CEO of Swedish Medtech company, Atos Medical AB, owned by PAI partners, 2019-2022. President and CEO of the Danish public biotech company, Zealand Pharma A/S, 2015-2019. CEO of Dako A/S, 2013-2014. Leadership roles at Novo Nordisk A/S, including being Corporate Vice President of Global Marketing, Market Access & Commercial Excellence, 2002-2013. Management Consultant in McKinsey & Company, 2000-2002. Education- 2000: MSc in International Marketing and Management, Copenhagen Business School, Denmark. 1998: MBA, Solvay Business School, ULB, Belgium.

Mr Larsen joined Novo Nordisk in 2007 and has held various leadership roles across multiple geographies and organisational levels. His experience includes functional responsibility for Commercial Affairs and Strategy in International Operations and leading operations in numerous African countries, the Middle and Near East, as well as the Commonwealth of Independent States. In 2022, Mr Larsen was promoted to senior vice president for the North West Europe region, spanning 15 countries. In 2024, during a corporate restructure, he was appointed senior vice president for the Europe and Canada region, leading a diverse portfolio of 40 countries. In August 2025, Mr Larsen was promoted to executive vice president of International Operations, based in Zurich, overseeing all global commercial units, excluding the US. Prior to joining Novo Nordisk, Mr Larsen worked as a policy adviser in the Danish and European Parliaments, with a focus on economic policy, healthcare, and tax reforms.

Effective 7 August 2025, Mr Doustdar was appointed as president and chief executive officer. Mr Doustdar joined Novo Nordisk in 1992 as an office clerk in Vienna, Austria. From 1993 through 2007 he took up various positions in finance, IT, logistics, operations and marketing, within various parts of Novo Nordisk's emerging markets, first in Vienna and subsequently in Athens and Zurich before he was appointed general manager of Novo Nordisk Near East, based in Turkey, in 2007. In 2010 Mr Doustdar was promoted to vice president of Business Area Near East and in 2012 he re-located to Malaysia to head the Business Area Oceania South East Asia. In 2013 he was promoted to senior vice president of Novo Nordisk's International Operations, and in April 2015 Mr Doustdar was promoted to executive vice president, continuing his responsibility for Novo Nordisk's International Operations. In September 2016 Mike Doustdar assumed additional geographical responsibilities and was promoted to executive vice president for an expanded International Operations, leading all commercial units globally, except for the US and Canada. Effective January 1, 2025, Canada was integrated into International Operations.

Mr Mejlvang joined Novo Nordisk in 2002 and has since held more than 10 different positions across R&D, manufacturing and commercial operations. From 2004 to 2019, he served in various leadership roles across CMC & Product Supply, including assignments in France. In 2019, Mr Mejlvang transitioned to senior leadership roles in Global Operations, where he served as General Manager for Denmark & Iceland. In 2022, he was appointed General Manager and President of Novo Nordisk Pharma Ltd. in Japan. Effective 1 January 2026, Mr Mejlvang was promoted executive vice president of CMC & Product Supply.

Ms Bogebjerg joined Novo Nordisk in 2007 as a project coordinator and cLEAN partner in our Chemistry, Manufacturing & Control (CMC) Supply function. She held numerous management positions of increasing seniority and complexity between 2010 and 2018, becoming corporate vice president of Sourcing Operations, Device & Supply chain, in 2019. In 2022, she was appointed corporate vice president of Oral Finished Products, and was promoted the following year to senior vice president of Emerging Technologies, where she oversaw the rapid upscaling of a Small Molecules organisation and business unit - including extensive M&A activities. In 2025, Ms Bogebjerg was promoted to executive vice president of Quality, IT & Environmental Affairs. Later in 2025, environmental affairs moved out of Ms Bogebjerg's area of responsibility.